中国全科医学
中國全科醫學
중국전과의학
CHINESE GENERAL PRACTICE
2014年
21期
2472-2477
,共6页
张林%张云%张智峰%张文涵%方春晓%于丽艳
張林%張雲%張智峰%張文涵%方春曉%于麗豔
장림%장운%장지봉%장문함%방춘효%우려염
哮喘%多态性,单核苷酸%Meta分析%整合素和金属蛋白酶域33
哮喘%多態性,單覈苷痠%Meta分析%整閤素和金屬蛋白酶域33
효천%다태성,단핵감산%Meta분석%정합소화금속단백매역33
Asthma%Polymorphism,singlenucleotide%Meta-analysis%ADAM33
目的:探讨整合素和金属蛋白酶域33(ADAM33)基因V4(rs2787094G>C)多态性与支气管哮喘易患性的关系。方法检索中国生物医学文献数据库( CBM )、维普网、万方数据知识服务平台、中国知网( CNKI )、PubMed、 EMBase、 Google学术、 Web of Science 等电子数据库,检索范围均从建库至2013年8月,筛选符合纳入标准的文献,由两位研究员进行数据收集、提取。采用Stata 12.0软件进行Meta分析。结果最终共纳入8篇文献,均为病例对照研究,共包括2128例支气管哮喘患者(病例组)和3134例健康对照者(对照组)。 Meta分析结果显示:在等位基因模型和显性模型中, ADAM33基因V4多态性与支气管哮喘易患性有关〔G与C: OR=1.58,95%CI (1.14,2.18), P=0.006; GG+GC与CC: OR=1.42,95%CI (1.25,1.60), P=0.000〕。亚组分析结果显示:对照组来源为普通人群时,在等位基因模型和显性模型中, ADAM33基因V4多态性与支气管哮喘易患性有关〔G与C: OR=1.58,95%CI (1.06,2.35), P=0.024; GG+GC与CC: OR=1.40,95%CI (1.22,1.60), P=0.000〕;对照组来源为医院人群时,在等位基因模型中, ADAM33基因V4多态性与支气管哮喘易患性无关〔OR=1.57,95%CI (0.73,3.37), P=0.244〕,在显性模型中, ADAM33基因V4多态性与支气管哮喘易患性有关〔OR=1.53,95%CI (1.12,2.08), P=0.000〕。采用聚合酶链反应-限制性片段长度多态性检测法(PCR-RFLP)进行检测时,在等位基因模型和显性模型中, ADAM33基因V4多态性与支气管哮喘易患性有关〔G与C: OR=2.21,95%CI (1.44,3.40), P=0.001; GG+GC与CC: OR=2.29,95%CI (1.88,2.78), P=0.000〕;采用其他检测方法时,在等位基因模型和显性模型中, ADAM33基因 V4多态性与支气管哮喘易患性无关〔G 与C: OR =1.07,95%CI (0.94,1.21), P =0.314; GG+GC与CC: OR=1.02,95%CI (0.87,1.20), P=0.769〕。结论 ADAM33基因V4多态性可能与支气管哮喘易患性增加有关,有可能作为早期诊断支气管哮喘的分子标志物。
目的:探討整閤素和金屬蛋白酶域33(ADAM33)基因V4(rs2787094G>C)多態性與支氣管哮喘易患性的關繫。方法檢索中國生物醫學文獻數據庫( CBM )、維普網、萬方數據知識服務平檯、中國知網( CNKI )、PubMed、 EMBase、 Google學術、 Web of Science 等電子數據庫,檢索範圍均從建庫至2013年8月,篩選符閤納入標準的文獻,由兩位研究員進行數據收集、提取。採用Stata 12.0軟件進行Meta分析。結果最終共納入8篇文獻,均為病例對照研究,共包括2128例支氣管哮喘患者(病例組)和3134例健康對照者(對照組)。 Meta分析結果顯示:在等位基因模型和顯性模型中, ADAM33基因V4多態性與支氣管哮喘易患性有關〔G與C: OR=1.58,95%CI (1.14,2.18), P=0.006; GG+GC與CC: OR=1.42,95%CI (1.25,1.60), P=0.000〕。亞組分析結果顯示:對照組來源為普通人群時,在等位基因模型和顯性模型中, ADAM33基因V4多態性與支氣管哮喘易患性有關〔G與C: OR=1.58,95%CI (1.06,2.35), P=0.024; GG+GC與CC: OR=1.40,95%CI (1.22,1.60), P=0.000〕;對照組來源為醫院人群時,在等位基因模型中, ADAM33基因V4多態性與支氣管哮喘易患性無關〔OR=1.57,95%CI (0.73,3.37), P=0.244〕,在顯性模型中, ADAM33基因V4多態性與支氣管哮喘易患性有關〔OR=1.53,95%CI (1.12,2.08), P=0.000〕。採用聚閤酶鏈反應-限製性片段長度多態性檢測法(PCR-RFLP)進行檢測時,在等位基因模型和顯性模型中, ADAM33基因V4多態性與支氣管哮喘易患性有關〔G與C: OR=2.21,95%CI (1.44,3.40), P=0.001; GG+GC與CC: OR=2.29,95%CI (1.88,2.78), P=0.000〕;採用其他檢測方法時,在等位基因模型和顯性模型中, ADAM33基因 V4多態性與支氣管哮喘易患性無關〔G 與C: OR =1.07,95%CI (0.94,1.21), P =0.314; GG+GC與CC: OR=1.02,95%CI (0.87,1.20), P=0.769〕。結論 ADAM33基因V4多態性可能與支氣管哮喘易患性增加有關,有可能作為早期診斷支氣管哮喘的分子標誌物。
목적:탐토정합소화금속단백매역33(ADAM33)기인V4(rs2787094G>C)다태성여지기관효천역환성적관계。방법검색중국생물의학문헌수거고( CBM )、유보망、만방수거지식복무평태、중국지망( CNKI )、PubMed、 EMBase、 Google학술、 Web of Science 등전자수거고,검색범위균종건고지2013년8월,사선부합납입표준적문헌,유량위연구원진행수거수집、제취。채용Stata 12.0연건진행Meta분석。결과최종공납입8편문헌,균위병례대조연구,공포괄2128례지기관효천환자(병례조)화3134례건강대조자(대조조)。 Meta분석결과현시:재등위기인모형화현성모형중, ADAM33기인V4다태성여지기관효천역환성유관〔G여C: OR=1.58,95%CI (1.14,2.18), P=0.006; GG+GC여CC: OR=1.42,95%CI (1.25,1.60), P=0.000〕。아조분석결과현시:대조조래원위보통인군시,재등위기인모형화현성모형중, ADAM33기인V4다태성여지기관효천역환성유관〔G여C: OR=1.58,95%CI (1.06,2.35), P=0.024; GG+GC여CC: OR=1.40,95%CI (1.22,1.60), P=0.000〕;대조조래원위의원인군시,재등위기인모형중, ADAM33기인V4다태성여지기관효천역환성무관〔OR=1.57,95%CI (0.73,3.37), P=0.244〕,재현성모형중, ADAM33기인V4다태성여지기관효천역환성유관〔OR=1.53,95%CI (1.12,2.08), P=0.000〕。채용취합매련반응-한제성편단장도다태성검측법(PCR-RFLP)진행검측시,재등위기인모형화현성모형중, ADAM33기인V4다태성여지기관효천역환성유관〔G여C: OR=2.21,95%CI (1.44,3.40), P=0.001; GG+GC여CC: OR=2.29,95%CI (1.88,2.78), P=0.000〕;채용기타검측방법시,재등위기인모형화현성모형중, ADAM33기인 V4다태성여지기관효천역환성무관〔G 여C: OR =1.07,95%CI (0.94,1.21), P =0.314; GG+GC여CC: OR=1.02,95%CI (0.87,1.20), P=0.769〕。결론 ADAM33기인V4다태성가능여지기관효천역환성증가유관,유가능작위조기진단지기관효천적분자표지물。
ObjectiveToevaluatetherelationshipbetweenV4(rs2787094G>C)polymorphismsinadisintegrin and metalloproteinase 33 (ADAM33) gene and liability of bronchial asthma .Methods Relevant studies were searched for in CBM, VIP, Wanfang, CNKI, PubMed, EMBase, Google Scholar, and Web of Science databases from their inception to Au-gust 2013.Data was collected and extracted by two researchers , and Stata 12.0 software was used to performed a Meta -analy-sis.Results A total of 8 literatures of randomized controlled studies were included , including 2 128 asthma patients and 3 134 healthy controls.By Meta-analysis, in allele and dominant models, ADAM33 gene V4 polymorphism was related to liability of bronchial asthma 〔G vs.C: OR=1.58, 95%CI (1.14, 2.18), P=0.006; GG+GC vs.CC: OR=1.42, 95%CI (1.25, 1.60), P=0.000〕.By subgroup analysis, when controls were general people , in allele and dominant models, ADAM33 gene V4 polymorphism was related to liability of bronchial asthma 〔G vs.C: OR=1.58, 95%CI (1.06, 2.35), P=0.024; GG+GC vs.CC: OR=1.40, 95%CI (1.22, 1.60), P=0.000〕; When control group were from hospital , in allele models, ADAM33 gene V4 polymorphism was not related to liability of bronchial asthma 〔OR=1.57, 95%CI (0.73, 3.37), P=0.244〕, and in dominant models , ADAM33 gene V4 polymorphism was related to liability of bronchial asthma 〔OR=1.53, 95%CI ( 1.12, 2.08 ), P =0.000〕. By polymerase chain reaction - restricted fragment length polymorphisms ( PCR-RFLP) , in allele and dominant models , ADAM33 gene V4 polymorphism was related to liability of bronchial asthma 〔G vs.C: OR=2.21, 95%CI (1.44, 3.40), P =0.001; GG +GC vs.CC: OR =2.29, 95%CI (1.88, 2.78), P =0.000〕.By other detection methods , in allele and dominant models , ADAM33 gene V4 polymorphism was not related to liabil-ity of bronchial asthma 〔G vs.C: OR=1.07, 95%CI (0.94, 1.21), P=0.314; GG+GC vs.CC: OR=1.02, 95%CI (0.87, 1.20), P=0.769〕.Conclusion ADAM33 gene V4 polymorphism, probably related to liability of bronchial asthma , can be used as a molecular marker for early diagnosis of bronchial asthma .